- Home
- WVE vs DEA Comparison
WVE vs DEA Comparison
Compare WVE & DEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVE
- DEA
- Stock Information
- Founded
- WVE 2012
- DEA 2011
- Country
- WVE Singapore
- DEA United States
- Employees
- WVE N/A
- DEA N/A
- Industry
- WVE Biotechnology: Pharmaceutical Preparations
- DEA Real Estate Investment Trusts
- Sector
- WVE Health Care
- DEA Real Estate
- Exchange
- WVE Nasdaq
- DEA Nasdaq
- Market Cap
- WVE 915.6M
- DEA 1.1B
- IPO Year
- WVE 2015
- DEA 2015
- Fundamental
- Price
- WVE $6.97
- DEA $23.66
- Analyst Decision
- WVE Strong Buy
- DEA Hold
- Analyst Count
- WVE 17
- DEA 5
- Target Price
- WVE $19.94
- DEA $27.15
- AVG Volume (30 Days)
- WVE 2.4M
- DEA 557.0K
- Earning Date
- WVE 11-11-2025
- DEA 11-04-2025
- Dividend Yield
- WVE N/A
- DEA 7.61%
- EPS Growth
- WVE N/A
- DEA N/A
- EPS
- WVE N/A
- DEA 0.38
- Revenue
- WVE $93,946,000.00
- DEA $322,861,000.00
- Revenue This Year
- WVE N/A
- DEA $8.78
- Revenue Next Year
- WVE $10.02
- DEA $6.43
- P/E Ratio
- WVE N/A
- DEA $62.61
- Revenue Growth
- WVE N/A
- DEA 7.93
- 52 Week Low
- WVE $5.28
- DEA $19.33
- 52 Week High
- WVE $16.74
- DEA $36.31
- Technical
- Relative Strength Index (RSI)
- WVE 29.71
- DEA 62.45
- Support Level
- WVE $7.12
- DEA $22.76
- Resistance Level
- WVE $7.76
- DEA $23.54
- Average True Range (ATR)
- WVE 0.51
- DEA 0.51
- MACD
- WVE -0.32
- DEA 0.10
- Stochastic Oscillator
- WVE 0.57
- DEA 89.33
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.